[go: up one dir, main page]

BRPI0509305A - uso de um sensibilizador insulìnico, composição farmecêutica, e , kit - Google Patents

uso de um sensibilizador insulìnico, composição farmecêutica, e , kit

Info

Publication number
BRPI0509305A
BRPI0509305A BRPI0509305-8A BRPI0509305A BRPI0509305A BR PI0509305 A BRPI0509305 A BR PI0509305A BR PI0509305 A BRPI0509305 A BR PI0509305A BR PI0509305 A BRPI0509305 A BR PI0509305A
Authority
BR
Brazil
Prior art keywords
insulin sensitizer
pharmaceutical composition
kit
suppressed
effects
Prior art date
Application number
BRPI0509305-8A
Other languages
English (en)
Inventor
Shoichi Kanda
Kasushi Araki
Jun Ohsumi
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of BRPI0509305A publication Critical patent/BRPI0509305A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"USO DE UM SENSIBILIZADOR INSULìNICO, COMPOSIçãO FARMACêUTICA, E, KIT" Um objeto da presente invenção é prover um método altamente seguro para tratar uma doença, em que os efeitos colaterais (por exemplo, edema) sejam suprimidos ao mesmo tempo em que se mantenha excelentes efeitos farmacêuticos. E fornecida uma composição farmacêutica que inclui um sensibilizador insulínico como um ingrediente ativo, caracterizada em um ciclo de administração do sensibilizador insulínico em que a sua dosagem seja reduzida ou suprimida durante o período de administração, é repetido uma vez ou mais.
BRPI0509305-8A 2004-03-29 2005-03-25 uso de um sensibilizador insulìnico, composição farmecêutica, e , kit BRPI0509305A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004094598 2004-03-29
PCT/JP2005/005526 WO2005092382A1 (ja) 2004-03-29 2005-03-25 インスリン抵抗性改善剤を含有する糖尿病治療剤

Publications (1)

Publication Number Publication Date
BRPI0509305A true BRPI0509305A (pt) 2007-09-04

Family

ID=35055995

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0509305-8A BRPI0509305A (pt) 2004-03-29 2005-03-25 uso de um sensibilizador insulìnico, composição farmecêutica, e , kit

Country Status (8)

Country Link
US (1) US20070049515A1 (pt)
EP (1) EP1731170A1 (pt)
KR (1) KR20070011329A (pt)
CN (1) CN1972715A (pt)
BR (1) BRPI0509305A (pt)
CA (1) CA2560928A1 (pt)
TW (1) TW200536515A (pt)
WO (1) WO2005092382A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007058504A1 (en) * 2005-11-21 2007-05-24 Lg Life Sciences, Ltd. Novel compounds as agonist for ppar gamma and ppar alpha, method for preparation of the same, and pharmaceutical composition containing the same
TW200730173A (en) * 2005-12-16 2007-08-16 Sankyo Co Pharmaceutical composition enhancing production of adiponectin

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
EP0306228B1 (en) * 1987-09-04 1999-11-17 Beecham Group Plc Substituted thiazolidinedione derivatives
US5594016A (en) * 1992-12-28 1997-01-14 Mitsubishi Chemical Corporation Naphthalene derivatives
CZ293016B6 (cs) * 1995-06-01 2004-01-14 Sankyo Company Limited Benzimidazolové deriváty a farmaceutické prostředky s jejich obsahem
EA002357B1 (ru) * 1995-12-28 2002-04-25 Фудзисава Фармасьютикал Ко., Лтд. Производные бензимидазола
AR029876A1 (es) * 1998-05-11 2003-07-23 Takeda Pharmaceutical Compuesto de acido oxiiminoalcanoilo, composicion farmaceutica y agente para controlar receptores relacionados con retinoide que lo comprenden y su uso
TWI284533B (en) * 1999-05-24 2007-08-01 Sankyo Co Pharmaceutical composition for treating hyperglycemia, impaired glucose tolerance, diabetes complications and for improving insulin resistant
JP2002220336A (ja) * 2000-11-22 2002-08-09 Sankyo Co Ltd 縮合複素環化合物の塩酸塩を含有する糖尿病の予防薬、治療薬
WO2002051441A1 (en) * 2000-12-26 2002-07-04 Sankyo Company, Limited Medicinal compositions containing diuretic and insulin resistance-improving agent
IL159320A0 (en) * 2001-06-12 2004-06-01 Wellstat Therapeutics Corp Compounds for the treatment of metabolic disorders
US20050119314A1 (en) * 2002-04-05 2005-06-02 Sankyo Company, Limited Pharmaceutical composition comprising an ACAT inhibitor and an insulin resistance reducing agent
KR20040099394A (ko) * 2002-04-05 2004-11-26 상꾜 가부시키가이샤 Ａｃａｔ 저해제 및 인슐린 저항성 개선제를 함유하는의약 조성물

Also Published As

Publication number Publication date
TW200536515A (en) 2005-11-16
CN1972715A (zh) 2007-05-30
US20070049515A1 (en) 2007-03-01
KR20070011329A (ko) 2007-01-24
EP1731170A1 (en) 2006-12-13
WO2005092382A1 (ja) 2005-10-06
CA2560928A1 (en) 2005-10-06

Similar Documents

Publication Publication Date Title
BRPI0513200A (pt) uso de um anticorpo anti-igf-1r na preparação de um medicamento para tratamento combinado para malignidades não-hematológicas
BR112015029918A2 (pt) uso de alta dose de pridopidina para tratar a doença de huntington
PE20142319A1 (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero
HRP20121072T1 (hr) Postupci za davanje tetrahidrobiopterina, povezani pripravci i postupci mjerenja
BRPI0418029B8 (pt) formulação farmacêutica líquida, estável, adequada para administração parentérica que compreende um anticorpo agonista de cd40
BRPI0507966A (pt) uso de meloxicam para o tratamento de doenças respiratórias em porcos
NO20064186L (no) Substituerte pyrazolin sammensetninger for a redusere triglycerider i blod
BRPI0518266B8 (pt) medicamento oral de liberação modificada de pelo menos um princípio ativo sob a forma multimicrocapsular
BR112015026247A8 (pt) composto em combinação com um análogo de citidina, composição farmacêutica que os compreende, uso dos mesmos e kit
BRPI0411451A (pt) formas de dosagens orais de memantina
BR112012030641A2 (pt) métodos e composições para terapia farmacêutica oral
AR056824A1 (es) Tableta de neramexano con matriz de liberacion modificada
AR049518A1 (es) Composicion farmaceutica que comprende un agente siliconado y dos principios activos solubilizados
MX2009011900A (es) Curacion de herida diabetica.
PE20211199A1 (es) Uso de reboxetina para el tratamiento de narcolepsia
BR0313413A (pt) Uso da vacinação beta amilóide juntamente com um inibidor da cox-2 seletivo para o tratamento da doença de alzheimer
BR112012020377A8 (pt) utilização de um ou mais selecionado do grupo constituído por um composto da fórmula (i), uma mistura racêmica-diastereomérica e um isômero óptico do referido composto, e um sal farmaceuticamente aceitável e uma pródroga do mesmo, método, composição farmacêutica e kit para tratamento de caquexia e embalagem comercial
JP2019529569A5 (pt)
ATE410152T1 (de) Therapeutisches system mit amoxicillin und clavulansäure
PT1220676E (pt) Prevencao do cancro colorrectal
BRPI0418764A (pt) uso de espinosina ou um derivado ou sal da mesma fisiologicamente aceitável
BRPI0509305A (pt) uso de um sensibilizador insulìnico, composição farmecêutica, e , kit
AR048318A1 (es) Formulaciones de matriz orales que comprenden licarbazepina
HRP20100208T8 (hr) Postupak liječenja akutnog rinosinusitisa
EA200800075A1 (ru) Схема дозирования для празугреля

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]